Adolor Investor Challenges Cubist's $415M Takeover Bid
Adolor’s directors have breached their duty to shareholders by signing off on an inadequate offer just as the company’s marquee drug, Entereg, is gaining steam in the market and another potentially lucrative drug nears Federal Drug Administration approval, according to a complaint filed by Thomas Fellman in Delaware Chancery Court.
The deal is...
Already a subscriber? Click here to login